The no-reflow phenomenon associated with percutaneous coronary intervention

Its mechanisms and treatment

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In patients with acute coronary syndrome (ACS), the immediate therapeutic goal is to establish patency of the infarct-related artery and to achieve optimal myocardial tissue reperfusion. Coronary microvasculatures, however, are often damaged irreversibly due to myocardial ischemia and reperfusion, and flow to the previously ischemic myocardium is markedly reduced, a phenomenon known as the "no-reflow phenomenon". In clinical settings, percutaneous coronary intervention (PCI) may accelerate embolization of plaque gruels and microthrombi to the microvessels, which further reduces tissue perfusion. The microvascular dysfunction attenuates the beneficial impact of PCI. The extent of the no-reflow phenomenon correlates with infarct size, and it has additional prognostic information. Patients with the no-reflow phenomenon have poor functional and clinical outcomes. Recent advances in imaging modalities have enabled diagnosis of the no-reflow phenomenon and assessment of the mechanisms of the microvascular dysfunction in patients. Use of pharmacological interventions and catheter-based devices to retrieve embolic materials have been proposed, and some of them are associated with improvement in clinical outcomes. Thus, we should keep in mind that only the achievement of successful myocardial perfusion is associated with better functional and clinical outcomes in patients with ACS.

Original languageEnglish
Pages (from-to)2-11
Number of pages10
JournalCardiovascular Intervention and Therapeutics
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

No-Reflow Phenomenon
Percutaneous Coronary Intervention
Myocardial Reperfusion
Acute Coronary Syndrome
Microvessels
Perfusion
Therapeutics
Myocardial Ischemia
Myocardium
Catheters
Arteries
Pharmacology
Equipment and Supplies

Keywords

  • Cardiac function
  • Coronary intervention
  • Microcirculation
  • Myocardial infarction
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

@article{ab8222b184ba4323a6279ad4ffcbdb90,
title = "The no-reflow phenomenon associated with percutaneous coronary intervention: Its mechanisms and treatment",
abstract = "In patients with acute coronary syndrome (ACS), the immediate therapeutic goal is to establish patency of the infarct-related artery and to achieve optimal myocardial tissue reperfusion. Coronary microvasculatures, however, are often damaged irreversibly due to myocardial ischemia and reperfusion, and flow to the previously ischemic myocardium is markedly reduced, a phenomenon known as the {"}no-reflow phenomenon{"}. In clinical settings, percutaneous coronary intervention (PCI) may accelerate embolization of plaque gruels and microthrombi to the microvessels, which further reduces tissue perfusion. The microvascular dysfunction attenuates the beneficial impact of PCI. The extent of the no-reflow phenomenon correlates with infarct size, and it has additional prognostic information. Patients with the no-reflow phenomenon have poor functional and clinical outcomes. Recent advances in imaging modalities have enabled diagnosis of the no-reflow phenomenon and assessment of the mechanisms of the microvascular dysfunction in patients. Use of pharmacological interventions and catheter-based devices to retrieve embolic materials have been proposed, and some of them are associated with improvement in clinical outcomes. Thus, we should keep in mind that only the achievement of successful myocardial perfusion is associated with better functional and clinical outcomes in patients with ACS.",
keywords = "Cardiac function, Coronary intervention, Microcirculation, Myocardial infarction, Reperfusion",
author = "Hiroshi Itoh",
year = "2011",
month = "1",
doi = "10.1007/s12928-010-0034-z",
language = "English",
volume = "26",
pages = "2--11",
journal = "Cardiovascular Intervention and Therapeutics",
issn = "1868-4300",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The no-reflow phenomenon associated with percutaneous coronary intervention

T2 - Its mechanisms and treatment

AU - Itoh, Hiroshi

PY - 2011/1

Y1 - 2011/1

N2 - In patients with acute coronary syndrome (ACS), the immediate therapeutic goal is to establish patency of the infarct-related artery and to achieve optimal myocardial tissue reperfusion. Coronary microvasculatures, however, are often damaged irreversibly due to myocardial ischemia and reperfusion, and flow to the previously ischemic myocardium is markedly reduced, a phenomenon known as the "no-reflow phenomenon". In clinical settings, percutaneous coronary intervention (PCI) may accelerate embolization of plaque gruels and microthrombi to the microvessels, which further reduces tissue perfusion. The microvascular dysfunction attenuates the beneficial impact of PCI. The extent of the no-reflow phenomenon correlates with infarct size, and it has additional prognostic information. Patients with the no-reflow phenomenon have poor functional and clinical outcomes. Recent advances in imaging modalities have enabled diagnosis of the no-reflow phenomenon and assessment of the mechanisms of the microvascular dysfunction in patients. Use of pharmacological interventions and catheter-based devices to retrieve embolic materials have been proposed, and some of them are associated with improvement in clinical outcomes. Thus, we should keep in mind that only the achievement of successful myocardial perfusion is associated with better functional and clinical outcomes in patients with ACS.

AB - In patients with acute coronary syndrome (ACS), the immediate therapeutic goal is to establish patency of the infarct-related artery and to achieve optimal myocardial tissue reperfusion. Coronary microvasculatures, however, are often damaged irreversibly due to myocardial ischemia and reperfusion, and flow to the previously ischemic myocardium is markedly reduced, a phenomenon known as the "no-reflow phenomenon". In clinical settings, percutaneous coronary intervention (PCI) may accelerate embolization of plaque gruels and microthrombi to the microvessels, which further reduces tissue perfusion. The microvascular dysfunction attenuates the beneficial impact of PCI. The extent of the no-reflow phenomenon correlates with infarct size, and it has additional prognostic information. Patients with the no-reflow phenomenon have poor functional and clinical outcomes. Recent advances in imaging modalities have enabled diagnosis of the no-reflow phenomenon and assessment of the mechanisms of the microvascular dysfunction in patients. Use of pharmacological interventions and catheter-based devices to retrieve embolic materials have been proposed, and some of them are associated with improvement in clinical outcomes. Thus, we should keep in mind that only the achievement of successful myocardial perfusion is associated with better functional and clinical outcomes in patients with ACS.

KW - Cardiac function

KW - Coronary intervention

KW - Microcirculation

KW - Myocardial infarction

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84863000722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863000722&partnerID=8YFLogxK

U2 - 10.1007/s12928-010-0034-z

DO - 10.1007/s12928-010-0034-z

M3 - Article

VL - 26

SP - 2

EP - 11

JO - Cardiovascular Intervention and Therapeutics

JF - Cardiovascular Intervention and Therapeutics

SN - 1868-4300

IS - 1

ER -